Audit 414343

FY End
2025-12-31
Total Expended
$1.78M
Findings
0
Programs
7
Year: 2025 Accepted: 2026-09-30

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
84.268 FEDERAL DIRECT STUDENT LOANS $920,944 Yes 0
84.063 FEDERAL PELL GRANT PROGRAM $267,024 Yes 0
93.994 MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES $239,296 Yes 0
93.788 OPIOID STR $161,607 Yes 0
93.959 BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE $101,689 Yes 0
93.493 CONGRESSIONAL DIRECTIVES $46,031 Yes 0
93.889 NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM $44,000 Yes 0

Contacts

Name Title Type
HB23N95N7MZ2 Kevin Randall Auditee
3154707589 Michael Schoell Auditor
No contacts on file

Notes to SEFA

The accompanying schedule of expenditures of federal awards (the "Schedule") includes the federal award activity of Crouse Health System, Inc. and Affiliates under programs of the federal government for the year ended December 31, 2025. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of Crouse Health System, Inc. and Affiliates, it is not intended to and does not present the financial position, changes in net position, or cash flows of Crouse Health System, Inc. and Affiliates.
Expenditures reported on the Schedule are reported on the the accrual basis of accounting of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.
The Company has elected to use the 10% de minimis indirect cost rate permitted under the Uniform Guidance.